Tag : ACUTE LYMPHOBLASTIC LEUKEMIA

The GIMEMA ALL2820 trial evaluated a chemo-free strategy with ponatinib + blinatumomab vs. imatinib + chemotherapy in adults with newly diagnosed Ph+ ALL. The initial results show that the experimental arm achieved higher complete hematologic response (CHR) and minimal residual disease (MRD) negativity, along with improved event-free survival and overall survival, and a manageable safety profile.

Non-total body irradiation-based conditioning in next-generation sequencing-minimal residual disease (NGS-MRD)-negative B ALL was associated with high event-free and overall survival after allogeneic hematopoietic cell transplantation. These outcomes were comparable to historical TBI-based approaches, while post-HCT NGS-MRD status was strongly correlated with relapse risk, supporting the use of molecularly guided conditioning strategies.